Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan for early sarcomeric hypertrophic cardiomyopathy
2015-002283-16Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute / National Institutes of Health
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) and Hypertrophic Obstructive Cardiomyopathy (HOCM) comparing Valsartan with Placebo (2 arms). Primary endpoint: Composite total z score across domains in Group 1. Started Dec 2015; status: completed.
02
Drugs
valsartan
03
Conditions
hypertrophic cardiomyopathy (HCM)Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on 2015-002283-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002283-16.